GILD Gilead Sciences Inc.

65.3
+0.79  (+1%)
Previous Close 64.51
Open 64.83
Price To Book 3.66
Market Cap 82,699,542,909
Shares 1,266,455,481
Volume 5,730,401
Short Ratio
Av. Daily Volume 5,830,831
Stock charts supplied by TradingView

NewsSee all news

  1. Gilead Sciences Appoints Andrew Dickinson as Chief Financial Officer

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Andrew Dickinson has been appointed Chief Financial Officer (CFO), effective November 1. Mr. Dickinson currently serves as the company's Executive Vice President,

  2. Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis

    Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational, oral,

  3. GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS

      Foster City, Calif. and Mechelen, Belgium; October 11, 2019, 0.00 CET; – Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that Week 52 data from the registrational

  4. GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS

      Foster City, Calif. and Mechelen, Belgium; October 11, 2019, 0.00 CET; – Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that Week 52 data from the registrational

  5. Gilead Sciences to Release Third Quarter 2019 Financial Results on Thursday, October 24, 2019

    -- Conference Call and Webcast to Follow -- Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its third quarter 2019 financial results will be released on Thursday, October 24, after the market closes. At 4:30

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 trial to be initiated in 2018.
Yescarta (Axicabtagene Ciloleucel) and Utomilumab (PF-05082566)
Large B-Cell Lymphoma
Phase 3 trial did not meet primary endpoint - February 11, 2019.
Selonsertib (GS-4997) - STELLAR 4
Nonalcoholic steatohepatitis (NASH)
Phase 2 enrollment completed 1Q 2018.
Selonsertib (GS-4997)
Alcoholic Hepatitis
Phase 2 data due 4Q 2019.
Filgotinib and GS-9876
Sjogren’s syndrome
Phase 3 enrolment to be completed 2H 2020.
Cilofexor (GS-9674)
Primary sclerosing cholangitis
Phase 2 data released November 9, 2018.
GS-9674
Primary biliary cholangitis
Phase 2 trial to complete enrolment 3Q 2019.
GS-5734
Ebola
FDA Approval announced October 3, 2019.
F/TAF (Descovy)
Pre-exposure prophylaxis
Phase 2 data due 1H 2020.
Axicabtagene ciloleucel - (ZUMA-5)
Indolent B-Cell Non-Hodgkin Lymphoma
Phase 2 data due 4Q 2019.
Filgotinib and GS-9876
Cutaneous lupus erythematosus (CLE)
Phase 3 trial to be initiated 1H 2020.
Filgotinib - TORTUGA
Ankylosing spondylitis
Phase 3 trial to be initiated 4Q 2019.
Filgotinib - EQUATOR
Psoriatic arthritis
Phase 3 futility analysis 3Q 2017. Trial to continue.
Andecaliximab GS-5745
Gastric Cancer
Approved February 7, 2018.
Bictegravir/F/TAF
HIV
Phase 2 data 4Q 2018.
GS-9674
Nonalcoholic steatohepatitis (NASH)
Phase 3 data April 25, 2019 did not meet primary endpoint.
Selonsertib (GS-4997) - STELLAR 3
Nonalcoholic steatohepatitis (NASH)
Phase 2 data released October 24, 2017. Positive high dose data, low dose negative.
GS-0976
Nonalcoholic steatohepatitis (NASH)
Approval announced July 18, 2017.
Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
Hepatitis C virus (HCV)
Phase 2 ongoing.
Entospletinib
Chronic Graft Versus Host Disease (cGVHD)
Phase 3 data due 2Q 2020.
Filgotinib - SELECTION
Ulcerative colitis
Phase 3 enrolment to be completed 3Q 2020.
Filgotinib - DIVERSITY
Crohn’s disease
NDA filing due 4Q 2019.
Filgotinib
Rheumatoid arthritis (RA)
Phase 2 data due 4Q 2019.
Axicabtagene ciloleucel - (ZUMA-2)
Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) - cancer
Phase 2 pivotal trial enrolment to be completed 4Q 2019.
Axicabtagene ciloleucel - (ZUMA-3)
Adult patients with r/r ALL - cancer
Phase 1/2 data released 2Q 2019.
Axicabtagene ciloleucel - (ZUMA-4)
Pediatric and young adult patients with r/r ALL - cancer
2-year data at ASH 2018 noted 39% of patients were in an ongoing response. OS not yet reached.
Yescarta (axicabtagene ciloleucel)
Refractory Non-Hodgkin's Lymphoma (NHL) - cancer
Phase 1/2 data due 1H 2020.
Axicabtagene ciloleucel (ZUMA-6)
Refractory diffuse large B-cell lymphoma (DLBCL)
Phase 1 data due 4Q 2019.
Axicabtagene ciloleucel (ZUMA-8)
Chronic lymphocytic leukemia (CLL)
Phase 2 data due 4Q 2019.
GS-9131
HIV
Phase 3 enrollment to be completed 4Q 2019.
Axicabtagene ciloleucel (ZUMA-7)
Refractory diffuse large B-cell lymphoma (DLBCL)
Phase 2b 48-week data due 4Q 2019.
Cilofexor (GS-9674) and firsocostat (GS-0976) - ATLAS
Nonalcoholic steatohepatitis (NASH)
Phase 3 trial to be initiated 3Q 2019.
Selonsertib (GS-4997)
Diabetic kidney disease
Phase 1 initial data due 1H 2020.
Axicabtagene ciloleucel - KTE-C19 (ZUMA-11)
Phase 2 data due 4Q 2019.
GS-9688
HBV
Phase 2 trial to be initiated 3Q 2019.
Axicabtagene ciloleucel and rituximab/lenalidomide (ZUMA-14)
Phase 2 enrolment to be completed 1H 2020.
Axicabtagene ciloleucel - (ZUMA-12)
Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2 trial to be initiated 4Q 2019.
GS-4875
Ulcerative Colitis

Latest News

  1. Gilead Sciences Appoints Andrew Dickinson as Chief Financial Officer

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Andrew Dickinson has been appointed Chief Financial Officer (CFO), effective November 1. Mr. Dickinson currently serves as the company's Executive Vice President,

  2. Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis

    Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational, oral,

  3. GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS

      Foster City, Calif. and Mechelen, Belgium; October 11, 2019, 0.00 CET; – Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that Week 52 data from the registrational

  4. GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS

      Foster City, Calif. and Mechelen, Belgium; October 11, 2019, 0.00 CET; – Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that Week 52 data from the registrational

  5. Gilead Sciences to Release Third Quarter 2019 Financial Results on Thursday, October 24, 2019

    -- Conference Call and Webcast to Follow -- Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its third quarter 2019 financial results will be released on Thursday, October 24, after the market closes. At 4:30

  6. Gilead Sciences Submits New Drug Application for Filgotinib for the Treatment of Adults With Rheumatoid Arthritis in Japan

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the New Drug Application (NDA) for filgotinib, an investigational, oral, selective JAK1 inhibitor for the treatment of adults with rheumatoid arthritis (RA) has

  7. Gilead Sciences Appoints Merdad Parsey, MD, PhD as Chief Medical Officer

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Merdad Parsey, MD, PhD, will join the company as Chief Medical Officer, effective November 1. Dr. Parsey will be responsible for the company's global clinical

  8. Gilead Presents New Data From the Company's HIV Clinical Development Program and Latest Findings on the Impact of HIV Pre-exposure Prophylaxis (PrEP) at IDWeek 2019

    - Results from DISCOVER Trial Provide Bone and Renal Safety Profile Data from Participants who Switched from Truvada for PrEP® to Descovy for PrEP™ - - Analysis Illustrates the Significant and Independent Impact of

  9. U.S. Food and Drug Administration Approves Descovy® for HIV Pre-Exposure Prophylaxis (PrEP)

    - Descovy Demonstrated Non-inferior Efficacy and an Improved Bone and Renal Safety Profile Compared with Truvada® in People at Risk for Sexually Acquired HIV Infection in a Global Phase 3 Trial - Gilead Sciences, Inc.

  10. Companies Seek an Innovative Solution to the Growing Cancer Rates

    NEW YORK, Sept. 30, 2019 /PRNewswire/ -- Cancer is among the leading causes of death in the world as countries are burdened by a lack of access to adequate healthcare. In 2018, the World Cancer Research Fund (WCRF)

  11. Gene Therapy Treatments Offer Hope for Cancer Patients

    NEW YORK, Sept. 4, 2019 /PRNewswire/ -- Recent developments in gene therapy hold out hope for the treatment of a wide range of diseases, including fatal lung cancer. Genprex Inc. (NASDAQ:GNPX) (GNPX Profile) is focused

  12. Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10

    Webcast Available Through Gilead Corporate Website Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Daniel O'Day, Gilead's Chairman and Chief Executive Officer, will participate in a fireside chat at the Morgan

  13. Alberta Provides Access to Biktarvy® for the Treatment of HIV

    Gilead Canada recognizes the Government of Alberta for providing access to new treatment for people living with HIV In 2017, Alberta accounted for 11.7 per cent of reported HIV cases in Canada1 In clinical trials,

  14. Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration

    Foster City, Calif. and Mechelen, Belgium; 23 August 2019; 22.01 CET; regulated information –   Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the closing of the global

  15. Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration

    Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the closing of the global research and development collaboration agreement signed on July 14, 2019. This press release